Introduction
In the last decade the mapping of genes responsible for many rare but important monogenic diseases has become commonplace. The techniques of molecular biology and statistical genetics are now being applied to multifactorial disorders such as hypertension, asthma, diabetes, and ischaemic heart disease. These common diseases, responsible for most of the morbidity and mortality in the developed world, are thought to result from an interaction between multiple environmental and genetic influences. To the geneticist, hypertension is far from the ideal disease to study. It is complex (the result of an interplay between environment and genes), quantitative (the upper extreme of a continuous blood pressure distribution) and heterogeneous (likely to involve a different assortment of genes in different subjects). Nevertheless, in the last 5 years substantial advances have been made in our understanding of the role of genes in the regulation of blood pressure, with the promise of more to come. This review will focus on: (1) the epidemiological background, (2) the evidence for a genetic contribution to hypertension, (3) the methods by which complexdisease genes can be identified, together with their strengths and limitations, and (4) examples of some of the major findings and controversies in the field to date.
Epidemiology
Systolic and diastolic blood pressure (BP) display a unimodal, continuous distribution in populations, a feature characteristic of a quantitative trait with multiple determinants [1] . The risk of stroke, coronary Correspondence and offprint requests to: A. D. Hingorani, Clinical Pharmacology Unit, University of Cambridge, Addenbrooke's Hospital, Cambridge CBQ 2QQ, UK. artery disease, congestive cardiac failure and renal insufficiency increases with increasing BP and operates over the whole range of BP without threshold [2] . The diagnostic definition of hypertension is based on an assessment of the risk-benefit ratio of treatment for any given level of BP [3] . The BP cut-off levels for treatment may not necessarily be those best suited to the selection of subjects for genetic studies and, furthermore, it is not clear whether the genetic determinants of BP within the 'normal range' will be the same as those influencing the development of an elevated blood pressure. In Westernized societies BP rises with increasing age [4] . In rural or isolated populations, BP rises in childhood with somatic growth with little evidence of an age-related increase in BP in adult life [5] . However, migration studies have shown that the BP distribution in such populations shifts to a higher level on adopting a more Western lifestyle [6] and environmental factors such as diet (body weight), salt, and alcohol intake are implicated [7] .
If environmental factors determine the average population BP, what determines an individual's position or rank within the distribution? The phenomenon of 'tracking' (the tendency for an individual to maintain their BP rank over time) can be seen from an early age [8] , suggesting that the processes involved are genetic or programmed early in development. It has recently been shown that low birthweight and large placental size correlate with elevated BP in adult life, suggesting that prenatal environment may influence adult BP status [9] . A similar link has been demonstrated for ischaemic heart disease [10] , and the 'birthweight hypothesis' suggests that many common human diseases are the result of permanent alterations in physiology caused by foetal undernutrition at different stages of pregnancy [11] . The mechanism by which prenatal environment may determine the pattern of adult disease remains uncertain and other explanations for the observed data clearly exist. Low birthweight is associated with continued environmental deprivation throughout life, an established risk factor for cardiovascular disease [12] . Furthermore, it is conceivable that the same factors predisposing to adult cardiovascular disease (including hypertension) might confer a selective survival advantage to infants of low birthweight; low birthweight babies surviving into adulthood might be a preselected group who are at particular risk of cardiovascular disease.
Evidence for a genetic contribution to blood pressure
Animal models A number of animal models of heritable hypertension have been developed by successive inbreeding (brothersister matings) of animals with the highest blood pressures in a colony [13] . Rat models have been most extensively studied, but the effect is not species specific. Although the physiological characteristics of these models vary and their direct relevance to human hypertension is uncertain, they have shown that genetic factors can profoundly influence BP regulation, and provide useful tools for the study of the mechanisms of gene-gene and gene-environment interaction.
Family studies
Blood pressure (whether 'hypertensive' or 'normotensive') tends to be similar in members of the same family [14] . Families share the same environment as well as the same genes and twin and adoption studies have been used in an attempt to control for this potential confounder. Twin studies demonstrate a closer correlation between the BP of monozygotic twins (who share 100% of their genes) compared to dizygotic twins and non-twin sibs (who share 50% of their genes) [15] , but they fail to account for the effect of common uterine environment and may thus overestimate the influence of inheritance. Nevertheless, adoption studies clearly demonstrate a closer correlation of BP between natural sibs compared to adoptees [16] and it has been estimated that 30-60% of the variation in BP in a population can be attributed to genetic effects [17, 18] .
Single-gene disorders and hypertension in man
The advances in molecular biology during the last decade have allowed the identification of the molecular defects underlying a number of hypertensive singlegene disorders in man (Table 1 ). The relationship between the pathogenesis of such monogenic hypertensive disorders and the more common multifactorial forms of the disease is unknown. Important mutations in a given disease gene might be sufficient to result in hypertension inherited as a monogenic condition in affected pedigrees, whilst minor mutations in the same gene influence the variability in BP in the population at large, modified by the influences of additional genes and environment. The autosomal dominant syndrome described by Liddle et al. in 1963 [27] , for which the gene and mutations have recently been identified, can be used to illustrate this. Hypertension is accompanied by low renin, hypokalaemia. and reduced urinary A. D. Hingorani and M. J. Brown sodium excretion (as in Conn's syndrome), but the adrenal glands are normal and there is a marked suppression of aldosterone release. Furthermore, the blood pressure and electrolyte abnormalities are ameliorated by amiloride and triamterene (but not spironolactone) and, in the index case, were reversed by renal transplantation [28] . These observations suggested a primary abnormality of tubular sodium transport. Schimkets et al. [19] recently demonstrated causative mutations in a gene encoding the /?-subunit of a membrane-bound, amiloride-sensitive, epithelial sodium channel expressed in the distal convoluted tubule of the kidney. This suggests that the hypertension in Liddle's syndrome may result from the constitutive renal reabsorption of sodium mediated by the mutant channel, but confirmation of this hypothesis will require functional studies. Since the severity of the hypertension and the biochemical abnormalities in gene carriers is variable, this disorder may be underdiagnosed. Furthermore, a subset of so-called essential hypertensives are characterized by low plasma renin activities, suggesting that weaker activating mutations in the genes for this (or other) sodium channel isoforms might contribute to the more common multifactorial forms of hypertension.
Identification of blood-pressure determining genes
The classical genetic technique of positional cloning aims to map disease genes by demonstrating the co-segregation of a genetic marker with the disease (or trait) through successive generations in an affected pedigree. This type of approach requires the assumption that, if the marker and disease gene are physically close on the same chromosome, there is a low probability of recombination between them at meiotic cell division (an event at which there is an exchange of genetic information between homologous maternal and paternal chromosomes). Disease gene and marker are thus said to be linked. Linkage mapping identifies the chromosomal position of a disease locus by relating it to a gene marker, but, depending on the resolution of the markers used, may implicate a region as large as 10-20 megabases (Mb). Physical mapping of the disease gene then requires the laborious, large-scale sequencing of the region of linkage. Fortunately, as a result of the work of the Human Genome Mapping Project, the linked region may already be known to contain a gene or genes whose function suggests involvement in the disease process thereby bypassing the need for a large sequencing effort. The identification of genetic markers is thus the prerequisite for any form of genetic study.
The majority of the human genome consists of noncoding DNA interspersed with functional genes (in turn divided by non-coding introns) [29] . Non-coding DNA exhibits considerable sequence variability which is inherited in a Mendelian manner. This may result in the creation or removal of cutting sites for sequencespecific bacterial restriction endonucleases which mani- [20] Von Hippel-Lindau syndrome [21] AD Autosomal dominant polycystic AD kidney disease [22] 11-/? hydroxylase deficiency [23] AR Glucocorticoid remediable AD aldosteronism (GRA) [ fests as a variable pattern of fragments when genomic DNA from different individuals is exposed to a restriction enzyme and electrophoresed through agarose gels. Such restriction fragment length polymorphisms (RFLPs) serve as useful bi-allelic markers for mapping studies, but have been superseded for some applications by more highly variable repetitive DNA sequences. Up to 30% of the human genome comprises repetitive DNA whose function is largely unknown. Repetitive sequences vary from long tandem repetitions of short nucleotide sequences (satellites, minisatellites, and microsatellites) to longer sequences ranging from approximately 300 base pairs (bp) (short interspersed repeat elements, SINEs) to 6-7 kilobases (long interspersed repeat elements, LINEs) [29] . Microsatellites (most commonly 2 bp repeats) can be used as genetic markers and are of particular use in mapping complexdisease genes. The length of a given microsatellite varies between individuals and length variation is inherited in a simple Mendelian manner. There are several advantages of such markers over RFLPs: they are highly polymorphic (multiple length alleles exist), evenly and frequently dispersed throughout the whole genome and readily typed using the polymerase chain reaction (PCR) [30] . Microsatellite maps of the mouse and human genomes have now been developed opening up the possibility of a positional cloning approach for complex-disease genes [31, 32] .
Nevertheless the mapping of such genes represents a formidable task [33] [34] [35] [36] . For most single-gene disorders the inheritance pattern is obvious and sufferers are clearly distinguished from unaffected family members. Disease onset is often (but not exclusively) in early life and thus parents and grandparents are still available for pedigree analysis. In contrast, essential hypertension has an obscure inheritance pattern, multigenerational families are not generally available (since disease detection has typically been in the fifth or sixth decade) and the effects of different genes (heterogeneity) or environmental influences (phenocopy) may result in clinically indistinguishable hypertensive phenotypes. Also, since BP is a quantitative variable, with hypertension representing one extreme of the continuum, it may be artificial to distinguish 'affected' and 'unaffected' subjects. In the face of these difficulties, a number of alternative approaches to the identification of hypertension genes have been explored.
Animal models
A clear advantage of studying the genetics of hypertension in an animal model is that directed mating experiments can be performed in large numbers of animals to facilitate segregation analysis [37] . The co-segregation of genetic markers and disease phenotype is studied by mating high-BP-strain and low-BPstrain animals, followed by brother-sister mating of the resulting cross. This type of approach has identified more than 10 BP-determining loci on a variety of chromosomes in a number of hypertensive rat strains, some of which appear to be strain-specific (see [38] for review). These findings emphasize the likely polygenic nature of the disease and confirm the impression that a different spectrum of genes may mediate different forms of hypertension. Animal models have also provided some evidence for gene-gene interaction (epistasis) in the control of BP. BP in the offspring can vary by as much as 20 mmHg, depending on which lowstrain animal is used in the initial mating. This suggests that additional genetic loci may modulate the effect of the gene of interest. More direct evidence for epistasis comes from crosses between the salt-sensitive Dahl rat and the Milan strain [39] . Offspring whose atrial natriuretic peptide (ANP) receptor and angiotensinconverting enzyme (ACE) genes are both derived from the Dahl strain have higher BP than those in whom only the ACE allele is of Dahl origin, suggesting an interaction between these two loci.
Animals also allow more profound genetic manipulation by methods other than selective breeding.
Transgenics (the incorporation of a foreign gene into a pluripotent embryonic stem (ES) cell to eventually generate a stable transgenic strain) [40, 41] , 'gene targeting' (the introduction of an inactivated or mutated gene into an ES cell in the place of the normal endogenous copy) [42, 43] , and 'antisense technology' (interference with the translation of specific proteins in an adult animal by the use of specific, complementary mRNA sequences) [43] have been used to elucidate the function of specific genes in the regulation of blood pressure.
A number of transgenic animal models of the reninangiotensin system have been developed to date, using rat and murine models [44] . However, not all the experimental manipulations undertaken in these animals have resulted in hypertension, despite expression of the transgene. Two explanations for this have been proposed. Firstly, primary hypertension is virtually unknown in mice, suggesting that while these animals are a suitable proving ground for transgenic technology, they may not be the most useful model for studies in hypertension. Secondly, the enzymatic activity of components of the renin-angiotensin cascade appears to be species-specific, therefore overexpression of a foreign gene may fail to have the desired biochemical effect. Thus, human renin does not interact with rat angiotensinogen except at high dose, and human angiotensinogen appears to be resistant to cleavage by rat renin. Despite these disappointments, one transgenic model has proved particularly interesting and has raised some provocative questions about the possible role of the tissue renin-angiotensin system in the development of hypertension. A transgenic rat (TGR (mREN2) 27) has been created by the insertion of the mouse Ren-2 renin gene into ES cells of a nonhypertensive, non-inbred Sprague-Dawley rat [45] . This animal develops fulminant hypertension, stroke, and renal failure unless subjected to lifelong antihypertensive treatment. Surprisingly, the animal has low circulating levels of renin and likewise suppressed renin activity in the kidney. Plasma angiotensinogen is unchanged, but angiotensin I and angiotensin II levels are also suppressed in comparison with controls. However, there are particularly high levels of renin in the adrenal cortex [46] and the hypertension is particularly sensitive to ACE inhibitors and losartan (but not spironolactone), suggesting that it is predominantly angiotensin-II-dependent. Vascular and cardiac renin activity is also enhanced, suggesting that overactivity of the tissue renin-angiotensin systems may be sufficient to elevate blood pressure [47] . Whether these findings can be extrapolated to human low-renin hypertension remains to be seen.
Further evidence for the role of the renin-angiotensin system in blood pressure regulation comes from two sources. A recent experiment in which the ACE gene of the mouse was disrupted by gene targeting resulted in a reduction in BP (of 15-20 mmHg) and serum ACE activity in male mice heterozygous for the null mutation [48] . Female heterozygotes, who also A. D. Hingorani and M. J. Brown displayed reduced serum ACE activity, had normal BP. The reason for the sex-specific effect is not clear.
In another novel approach, Wielbo et al. [49] showed that intracerebroventricular injection of a complementary antisense oligonucleotide targeted to angiotensinogen mRNA resulted in a reduction in BP in the spontaneously hypertensive rat (SHR) and was associated with a reduction in central nervous system angiotensinogen production. This effect was not produced by arterial injection of the antisense oligonucleotide nor by central injection of the sense oligonucleotide, suggesting a role for the neural renin-angiotensin system in the regulation of BP in this model. Using such approaches it may be possible to dissect out the effects of single genes in complex systems. These techniques are likely to become important tools in future research aimed at confirming the findings of classical breeding experiments.
While animal models provide useful information on the possible mechanisms of normal and abnormal BP regulation, the results of animal experiments cannot be extrapolated directly to human hypertension. This limitation has provided the impetus for the more difficult, but potentially more rewarding, study of the genetic determinants of BP in man.
Human studies
Conventional linkage analysis for a monogenic disorder compares the observed segregation of gene markers and trait in an affected pedigree with that predicted by a particular model of disease inheritance. The complexities of studying multifactorial disease dictate the use of alternative strategies which aim to overcome or minimize the confounding effects of heterogeneity, phenocopy, and the environment [50] . Most of these methods make no a priori assumptions about the pattern of disease inheritance. Since blood pressure is a continuous variable, it is possible that those genetic approaches which analyse BP as a quantitative trait will be the most useful, but there are practical difficulties in recruiting appropriate patient populations prior to the commencement of antihypertensive treatment. Therefore, most studies to date have analysed hypertension and normotension as simple dichotomous traits. The problem of heterogeneity may be reduced by selecting homogeneous subsets of hypertensives on the basis of common (often genetically determined) biochemical characteristics or intermediate phenotypes [51] , such as urinary kallikrein excretion, non-modulating hypertension, familial dyslipidaemic hypertension, sodium-lithium countertransport activity and insulin resistance [52] . Two major types of study design have been used to assess the genetics of complex disorders in humans: association studies (based on linkage disequilibrium) and allele sharing methods.
Association studies
The simplest form of association study is a comparison of the frequency of a genetic marker in unrelated cases and controls [50] . An increase in marker allele frequency in cases compared to control subjects is indirect evidence for the involvement of a neighbouring gene (with its putative functional mutation) in the pathogenesis of the disease. The basis of this type of analysis is the phenomenon of linkage disequilibrium, which is said to be present when alleles at two genetic loci occur together in populations more frequently than would be expected from their random assortment. Normally, alleles at two markers situated on different chromosomes would be expected to segregate completely independently. However, when two loci (one disease and the other marker) lie so close on the same chromosome that recombination between the two is extremely rare, disease sufferers carry the marker far more frequently than controls, provided that certain conditions prevail: the disease-causing allele must have arisen from a single ancestral mutation and the rate of new mutation at the marker or disease loci must be low [53] . If these conditions did not apply, different disease mutations would probably come to be surrounded by a different spectrum of marker alleles and association would be impossible to prove. Theoretical arguments based on such assumptions suggest that mapping by linkage disequilibrium works best with data from genetically isolated populations derived from a few common founders.
The validity of case-control studies is critically dependent on the suitable selection of cases and controls. Ideally these two groups should be part of the same larger population and differ genetically only at one or more blood-pressure-determining loci. If cases and controls are not selected in the same way, there is a danger that undetected selection bias may confound the analysis.
Since association studies are critically dependent on the close proximity of marker and disease alleles, such an analysis is usually only performed for markers in or around a known gene whose protein product is likely, on theoretical grounds, to have a role to play in BP regulation (a candidate gene).
Allele-sharing methods
This approach examines the average number of marker alleles shared by sibling-(or other relative-) pairs concordant for a disease and compares this value to that expected by chance (random segregation of marker and disease loci) [50] . Under conditions of no linkage, sib-pairs would be expected to share 2, 1, or 0 marker alleles 25%, 50%, and 25% of the time respectively. The demonstration of a statistically significant excess of shared alleles is evidence of linkage to a marker locus [54] . Since allele sharing approaches are typically applied to a single generation of disease sufferers they are independent of the pattern of disease inheritance and are, therefore, highly suited to the analysis of a complex disorder with late onset. One critical assumption made by such an analysis relates to the ancestral origin of shared alleles. Alleles shared by a pair of sibs are said to be identical by descent (IBD) if they are 579 inherited from the same parental chromosome. If parental data is unavailable, this cannot be verified directly and the assumption is made that all shared alleles (i.e. alleles identical by state [IBS]) have common ancestry. However, IBS may not equate with IBD for those marker alleles (e.g. bi-allelic RFLPs) with a high population prevalence. Highly polymorphic microsatellite markers with multiple allelic variants are thus the preferred marker type for this type of analysis.
In common with classical linkage approaches, allelesharing methods implicate larger segments of the genome than association studies, such that they can be applied not only to candidate genes, but also to the genome at large as part of a genome-wide positional cloning strategy. With the advent of high-resolution microsatellite maps of the human genome and automated microsatellite analysis, the positional cloning of any complex-disease gene is now a realizable goal. The major limitations at present are the expense of the technology and the recruitment of sufficiently large populations of affected relatives. The number of subjects required to reliably detect linkage for a disease such as hypertension is the matter of some debate. The power of such an approach depends on a variety of factors including the informativity and distribution of the markers used, the number of genes involved and the magnitude of the genetic effects at each disease locus [55] . Conservative estimates suggest that at least several hundred pairs might be required, but the figure may lie closer to 1000. Variants of the general allelesharing approach include of the use any diseaseaffected member of a pedigree (affected pedigree member (APM) method) [56] and the use of siblings discordant for the disease [57] . Allele-sharing methods can also be applied to quantitative traits (including hypertension) by relating the number of alleles shared to the difference in the quantitative variable between the two members of the sibship (quantitative trait locus (QTL) analysis).
From markers to disease genes
Genetic markers are the fundamental tools of genetic analysis, but these markers are rarely themselves the cause of the disease process. They can do no more than implicate a segment of the genome which may contain many candidate genes. Disease-susceptibility mutations are likely to reside in the coding regions of these genes, where they may alter the amino-acid sequence and thus the activity of the encoded protein product, or in the upstream or downstream regulatory regions, where they may influence levels of gene expression [58] . The identification of such mutations by DNA sequencing is the ultimate aim of this type of work. A number of mutation-scanning techniques based upon the polymerase chain reaction have recently been developed to facilitate the identification of mutations in candidate disease genes. These include singlestrand conformation polymorphism analysis (SSCP), heteroduplex analysis, and denaturing gradient gel electrophoresis. The details of these methods have been reviewed elsewhere [59, 60] . Using such techniques, common individual variation in coding DNA can readily be identified. The challenge is to demonstrate the functional relevance of these mutations at a biochemical or physiological level, remembering that, for complex diseases, mutations are likely to result in subtle disturbances rather than a gross loss of function. To fulfil Koch's postulates, confirmation of the pathological relevance of an identified mutation requires transfection and expression of the variant sequence in a cell line, or the creation of a model of the disease in a transgenic animal which houses the variant gene.
Candidate gene studies in animal and human hypertension
Although a few rodent studies have attempted a restricted positional cloning approach to identify hypertension genes, most studies in rodents and all investigations in man thus far have used a candidate gene approach.
Research in the fields of physiology and pharmacology has suggested a spectrum of likely candidate genes for essential hypertension. A number of systems serve to regulate both blood-vessel tone and circulating blood volume. A genetically determined variability in any one of these systems, in conjunction with the appropriate environmental stressor, could manifest as an elevation in BP. An increase in total peripheral resistance is characteristic of the established phase of essential hypertension. Folkow suggested that this increased resistance alone, whether a trigger or a response, could itself sustain the BP elevation [61] . Recent studies have suggested that this increase in resistance is partly the result of a reduction in luminal diameter by vascular remodelling in small blood vessels [62] , implicating neuroendocrine or local autocrine or paracrine growth regulators as additional candidate genes for hypertension.
The study of many human candidates has been motivated by positive findings in rat models, but caution must be exercised in extrapolating directly from animal models to man. Several human studies (notably those concerning the ACE, renin and S A gene loci) have failed to confirm positive findings in rat models (vide infra). Much attention has been directed towards the genes of the renin-angiotensin system because of its importance in cardiovascular homeostasis. However, genes encoding components of the sympathoadrenal system, genes for local vasoconstrictor/vasodilator substances, adrenal steroid biosynthetic enzymes, and cell membrane ion transporters are additional possible candidates.
Renin
Elevated levels of circulating renin appear to be responsible for a few well-defined subsets of secondary hypertension, including rare renin-secreting tumours, renal artery stenosis and end stage renal failure. The A. D. Hingorani and M. J. Brown role of renin in essential hypertension is less clear. Most hypertensives have normal circulating renin levels and up to 30% have low-normal levels. The reninsodium profile (a measure of circulating renin corrected for volume status) appears to be an independent risk marker for myocardial infarction in individuals with essential hypertension [63] . A number of animal studies have demonstrated linkage of the renin locus with hypertension [64, 65] , but, several association [66, 67] and one affected sib-pair study [68] have failed to demonstrate the same result in man. Even in the rat it is not clear whether the renin gene itself or an adjacent gene is the culprit, since sequencing of the renin gene of the salt-sensitive Dahl strain (a strain in which linkage to the renin locus had previously been established) failed to demonstrate significant mutations in the coding or regulatory regions [69] .
A ngio tensinogen
Cleavage of angiotensinogen (AGT) by renin is the rate-limiting step in the generation of angiotensin II, and several lines of evidence point to a relationship between circulating AGT and BP. AGT levels correlate with BP in man [70] , AGT levels are higher in hypertensives than controls and are higher in the offspring of hypertensives [71] . Blood pressure levels are also increased in transgenic mice overexpressing the AGT gene [72] . Two allele-sharing studies in man have reported linkage of the AGT locus on chromosome lq with hypertension [73, 74] , but association studies using a common polymorphism in exon 2 of the gene (encoding a Met 235 -»Thr amino acid variant) have been inconsistent [73] [74] [75] [76] [77] . By virtue of its location in the mature peptide, it seems unlikely that this amino acid substitution could alter the kinetics of the reaction catalysed by renin. However, this polymorphism is associated with individual variation in plasma levels of AGT (with higher levels tracking with the T235 allele) [73, 78] . Further studies are required to establish whether this marker is in linkage disequilibrium with a variant controlling AGT gene expression. A recent study suggests that this locus may also account for part of the genetic predisposition to pre-eclampsia [79] , although further confirmation of this finding is required.
Angiotensin-convertingenzyme (ACE)
ACE has a central role in both the renin-angiotensin and kallikrein-kinin pathways, promoting the formation of angiotensin II and inactivating bradykinin. ACE inhibitors are important antihypertensive agents and may also have a beneficial role in the prevention of cardiac hypertrophy and in the remodelling process following acute myocardial infarction [80, 81 ] . An insertion (I)/deletion (D) polymorphism in intron 16 of the ACE gene (chromosome 17q) has been associated with individual variation in the circulating (and possibly cellular) levels of ACE [82, 83] , although this polymorphism is unlikely to represent a functional mutation. The D allele has been associated with an increased risk of myocardial infarction [84] , ischaemic heart disease [85] , left ventricular hypertrophy [86] , and sudden death [87] in a number of case-control studies, but an increasing number of negative studies are now being reported [88, 89] . The situation in hypertension is equally controversial. Negative association and linkage studies predominate [90, 91] , although a few case-control studies have found an age-related excess of II subjects among hypertensives when compared to normotensive controls [92, 93] . The assertion that this is a consequence of an excess mortality in elderly hypertensives carrying the D allele, leading to population enrichment with II homozygotes with increasing age, remains unproven [93] . Rat chromosome 10 (which contains the rat ACE gene) has been linked to hypertension [94, 95] , this area also contains a number of other interesting candidate genes including growth hormone and phenylethanolamine-A^-methyltransferase (PNMT). Direct sequencing of these candidate genes in hypertensive and normotensive strains will be required to identify which, if any, of these genes carries an important functional mutation.
Angiotensin II type 1 receptor (ATJtL)
Angiotensin II type 1 receptors mediate the vasoconstrictive and salt-conserving actions of the renin-angiotensin system [96] . In man, a polymorphism in the 3' untranslated region of the AT,R gene (A->C 1166 ) was associated with hypertension in a case-control study [97] but, linkage with a polymorphic dinucleotide repeat element in the A^R gene could not be demonstrated [97] . This discrepancy might be explained by the lower power of the affected-sib pair method of analysis, but further studies will be required to clarify this issue. The excess risk of myocardial infarction attributed to the D allele of the ACE gene appears to be operating almost exclusively in those subjects who also possess one or two copies of the C 1166 allele of the AT,R gene, suggesting a gene-gene (or epistatic) interaction between the two loci [98] . It is not clear whether the A->C 1166 variant is acting as a marker for differences in receptor density or activity. Molecular scanning of this receptor failed to identify a significant mutation in the coding region, but does not exclude the presence of a functional variant in the regulatory elements upstream or downstream of the gene [97] .
Endothelins (ET)
The endothelin family of peptides (ET-1, ET-2, and ET-3) are important paracrine vasoconstrictor peptides, synthesized predominantly by endothelial cells, which produce their major action on subadjacent vascular smooth muscle [99] . Each ET is derived from a larger precursor peptide encoded by distinct genes [100]. In addition, ETs have been shown to influence vascular smooth muscle proliferation, cardiac contraction and regulation of blood volume, the latter by altering the release of other regulatory substances (e.g. 581 renin, aldosterone, and ANP) and by direct influence on renal blood flow and sodium handling [101] . The ETs have been implicated in a number of vascular and renal pathologies [ 101 ] , but their role in the generation or maintainence of hypertension is the subject of debate [102] . Although evidence suggests that normal resting tone in the human vasculature is in part dependent on the vasoconstricting effects of ET-1 [103] , whether the elevated vascular resistance seen in established essential hypertension results from an increased generation of, or sensitivity to, endothelin is unclear [102] . Genetic studies in rat models have shown co-segregation of markers at the ET-3 and ET-2 loci with blood pressure [104, 105] . Studies of both these loci in man should be forthcoming. There is evidence that the ET-1 and the ET A receptor gene loci may interact to influence human blood pressure variation in the normal range (P. A. Stevens, personal communication). Mice heterozygous for an ET-1 gene 'knockout' were recently shown, to exhibit a higher blood pressure than the control animal, but these animals also exhibited severe craniofacial abnormalities and upper airway obstruction, and hypoxaemia may have been partly responsible for the paradoxical BP effect. Mice homozygous for the disrupted gene died in utero [106] . Further studies will be required to clarify the role of these peptides and their receptors in human hypertension.
Atrial natriureticpeptide (ANP) system
Atrial natriuretic peptide is one of a family of three hormones involved in vasodilatation, sodium excretion, and regulation of the renin-angiotensin axis [107] . They are the products of separate genes and exhibit different tissue distributions [107] . Animal studies have implicated the ANP-receptor locus in blood pressure control and suggest an interaction with the ACE gene locus [39] . This result was supported by a QTL analysis of chromosome 2 which contains genes not only for the ANP receptor, but also additional candidates including neutral endopeptidase, Na + , K + -ATPase a x isoform and calmodulin-dependent protein kinase II-delta loci [108] . Association studies of the ANP gene in man have been negative [109] .
Nitric oxide
Nitric oxide (NO) is an important regulatory molecule involved in cardiovascular homeostasis, neuronal transmission, and immune defence [110] . Genes for the three nitric-oxide synthase (NOS) enzymes, which generate NO using L-arginine and molecular oxygen as substrates, have been cloned and sequenced [111] [112] [113] . Isoforms I (brain) and III (endothelial) are constitutively expressed, but expression of isoform II (which may be found in a number of cell types) requires induction by a variety of cytokine and other stimuli [110] . Endothelium-derived NO promotes vascular smooth muscle cell (VSMC) relaxation, inhibits platelet aggregation and VSMC growth [110] . Studies using inhibitors of the enzyme, suggest that NO controls local vascular tone [114] and systemic blood pressure [115] . A number of animal [116, 117] and human [118, 119] studies have shown reduced NO generation, with normal NO sensitivity, in hypertensive blood vessels, but this finding is by no means universal [120] . Further, it is not clear whether this represents a primary endothelial defect, or is secondary to endothelial damage by chronic high arterial pressure. A genetic approach may help to resolve this controversy. Deng and Rapp [121] recently reported co-segregation of the inducible NOS locus with BP in crosses between the Dahl rat and both (Wistar-Kyoto) WKY and Milan normotensive (MNS) strains. In man, a single study of affected sib-pairs failed to demonstrate linkage of the endothelial NOS locus with hypertension [122] , but studies of genes encoding other isoforms of this enzyme in man are awaited.
Steroid biosynthetic enzymes
The adrenal cortex synthesizes glucocorticoids and mineralocorticoids and, in the appropriate setting, either can produce an elevation of BP [123] . A number of single-gene disorders alter the activity of key synthetic enzymes and produce rare heritable forms of hypertension. Mutations in the 11-/? hydroxylase gene result in enzyme deficiency and failure to metabolize hypertensinogenic steroids such as deoxycorticosterone and deoxycortisol, producing an autosomal recessive form of hypertension [124] . Salt-sensitive and saltresistant strains of the Dahl rat exhibit a number of sequence differences in the coding region of the 11-/? hydroxylase gene which cosegregate with adrenal steroid profile and BP [125] .
Glucocorticoid remediable aldosteronism is a rare autosomal dominant form of human hypertension resulting from the inheritance of a chimaeric 11-/? hydroxylase/aldosterone synthase gene. This gene (which comprises the upstream regulatory portion of 11-/? hydroxylase and the downstream synthetic portion of aldosterone synthase) was presumably formed by an unequal recombination event between these highly homologous genes during an ancestral meiotic cell division [126] . The transcription of the chimaeric gene is abnormally regulated by ACTH (and not angiotensin II), such that chimaeric steroids and aldosterone are secreted in excess and hypertension ensues. Suppression of ACTH release by dexamethasone reverses the BP elevation. The site of recombination varies between different pedigrees and in some individuals carrying the chimaeric gene, hypokalaemia, alkalosis, and mineralocorticoid excess are mild or absent, raising the possibility that this disorder may be underrecognised and may account for a significant proportion of so-called essential hypertensives. These observations suggest that steroid biosynthetic enzymes are possible candidate genes for the common forms of hypertension. Association and linkage studies of these gene loci are likely to follow in the near future.
A. D. Hingorani and M. J. Brown S A gene The S A gene was identified by a novel approach which makes no a priori assumption as to the likely nature of a BP-determining gene. The molecular technique known as differential cDNA hybridization revealed S A as a mRNA species showing marked overexpression in the kidneys of SHR compared to the WKY control strain [127] , S A gene markers were subsequently shown to cosegregate with BP in crosses between the SHR and WKY rats and to be associated with differential expression of the S A mRNA in the kidney of the SHR [128] . Although cloning of the equivalent gene in man led to an initial report of an association between a polymorphism at this locus and hypertension in a Japanese population [129] , this finding has not been confirmed by others [130] . Further progress will require clarification of the function of the S A gene product, but this general approach to the identification of novel BP candidates might eventually be applied directly to man.
Whole-genome scanning vs candidate-gene approach
The recent publication of the results of genome-wide scans for loci conferring susceptibility to insulindependent diabetes mellitus (IDDM) using the affected sibling-pair approach has shown the feasibility of such studies, given the appropriate patient material and financial resources [131, 132] . Loci for asthma and noninsulin-dependent diabetes mellitus are under investigation using this method, and studies in hypertension are sure to follow. Whether this approach proves as fruitful in hypertension as in IDDM remains to be seen. If the common forms of hypertension are determined by a small number of genes (each with large effect), it should be relatively easy to determine their location. However, if many genes each contribute to a small degree, they will prove much more difficult to locate, and arguably the search will have been less worthwhile. There remain clear concerns about the power of genome-wide scans, particularly their power to exclude genetic linkage at any locus without resort to very densely spaced markers and large numbers of subjects. One proposed strategy is a stepped approach, with an initial low-resolution scan (with a low stringency for a positive result) followed by a higherresolution analysis (with more conservative criteria for a positive result) confined to those regions of linkage identified by the first pass [55] . Once the chromosomal location for a disease has been identified with a high degree of certainty, methods such as association analysis (which depend on the phenomenon of linkage disequilibrium) will be required to further narrow the search and eventually identify disease genes. It may be argued that this laborious process could be bypassed by a direct assessment of candidate genes. In the case of IDDM, genome scanning showed that the insulin gene locus (IDDM 2) on chromosome 11 and the HLA locus (IDDM 1) on chromosome 6 demonstrated strongest linkage to the disease [131] . Although this observation does not directly implicate the HLA or insulin genes themselves in the susceptibility to IDDM, it could be argued that these gene loci might have been studied early on in a candidate-gene strategy based on the known pathogenesis of the condition. The alternative viewpoint is that such a strategy is blinkered, by being restricted to the study of known genes. Such an approach would have been unlikely, for instance, to have identified the type of novel gene recently implicated in the pathogenesis of some forms of breast cancer [133] . It is likely that both strategies will be pursued, the genome-wide analysis by those centres with sufficient patient material, finances, and technology, and the candidate-gene strategy by other interested groups. The two approaches may prove to be complementary.
Conclusions
The obstacles encountered in identifying the genetic basis of complex human diseases are gradually being overcome by a variety of molecular and statistical approaches. The hypothesis that BP is regulated by a multiplicity of genes, of differing relative importance in different subsets of hypertension has largely been confirmed, at least in the rat. In addition, evidence for gene-gene interactions is accumulating in accordance with prior expectations. The positional cloning of BP loci in man is now eagerly awaited and will represent a major step towards the ultimate goal of cataloguing all the genes and all the mutations which predispose to the development of hypertension. It is hoped that this information will lead to a greater understanding of the mechanisms by which hypertension is generated, improvements in risk assessment, and the rational design of new drug therapies. Within the next few years, the marriage of molecular biology and classical physiology and pharmacology should move some way towards the final aim of a complete aetiological classification of hypertension.
